The certification is for products used in hematology instruments manufactured globally, including instruments from Abbott, Beckman Coulter, and Siemens Healthineers.

Last week, readers were most interested in a story about Tempus' expectations for its acquisition of cancer testing firm Ambry.

The US Food and Drug Administration granted clearances for various tests for infectious diseases, coagulation disorders, and drug susceptibility.

NEW YORK – Adaptive Biotechnologies on Thursday reported a 22 percent increase in Q3 revenues driven by an increase in minimal residual disease testing.

The firm said on Wednesday that it has been hiring key sales and marketing personnel as it prepares to ramp up sales in 2025 of its PreTRM proteomic test.

SensID manufactures reference materials and quality controls for molecular diagnostics with a focus on oncology and precision medicine.

The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.

The firm had received notice last year that it was out of compliance with a requirement to maintain a minimum $15 million market value of publicly held shares.

The company reported on Tuesday that its revenues jumped 8 percent in North America and Europe during the third quarter but fell slightly in the rest of the world.

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Fadel Alshalabi, owner and CEO of Crestar Labs, and Samuel Harris, owner of Flojo Recruiting, conspired to bill Medicare and Medicaid for millions of dollars in genetic test orders.

The firm reported that its adjusted diagnostics revenues rose less than 1 percent, excluding the COVID-19 rapid antigen testing business that the firm exited last year.